These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20368235)

  • 1. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease.
    Rutter MK; Nesto RW
    Diab Vasc Dis Res; 2010 Jan; 7(1):69-72. PubMed ID: 20368235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial.
    Sobel BE
    Coron Artery Dis; 2010 May; 21(3):189-98. PubMed ID: 20308880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The BARI 2D study].
    Mafrici A; Briguori C
    G Ital Cardiol (Rome); 2010 Oct; 11(10):711-7. PubMed ID: 21246772
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized trial of therapies for type 2 diabetes and coronary artery disease.
    ; Frye RL; August P; Brooks MM; Hardison RM; Kelsey SF; MacGregor JM; Orchard TJ; Chaitman BR; Genuth SM; Goldberg SH; Hlatky MA; Jones TL; Molitch ME; Nesto RW; Sako EY; Sobel BE
    N Engl J Med; 2009 Jun; 360(24):2503-15. PubMed ID: 19502645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
    Tamis-Holland JE; Lu J; Korytkowski M; Magee M; Rogers WJ; Lopes N; Mighton L; Jacobs AK;
    J Am Coll Cardiol; 2013 Apr; 61(17):1767-76. PubMed ID: 23500245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2014 Apr; 129(16):e460-1. PubMed ID: 24753557
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
    Khan AA; Chung MJ; Novak E; Brown DL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
    Brooks MM; Frye RL; Genuth S; Detre KM; Nesto R; Sobel BE; Kelsey SF; Orchard TJ;
    Am J Cardiol; 2006 Jun; 97(12A):9G-19G. PubMed ID: 16813734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
    Hlatky MA; Boothroyd DB; Melsop KA; Kennedy L; Rihal C; Rogers WJ; Venkitachalam L; Brooks MM;
    Circulation; 2009 Dec; 120(25):2550-8. PubMed ID: 19920002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
    Magee MF; Isley WL;
    Am J Cardiol; 2006 Jun; 97(12A):20G-30G. PubMed ID: 16813735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
    Barsness GW; Gersh BJ; Brooks MM; Frye RL;
    Am J Cardiol; 2006 Jun; 97(12A):31G-40G. PubMed ID: 16813736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group
    Am Heart J; 2008 Sep; 156(3):528-536, 536.e1-5. PubMed ID: 18760137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.
    Chaitman BR; Hardison RM; Adler D; Gebhart S; Grogan M; Ocampo S; Sopko G; Ramires JA; Schneider D; Frye RL;
    Circulation; 2009 Dec; 120(25):2529-40. PubMed ID: 19920001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of the BARI 2D and COURAGE trials of coronary artery disease.
    Kuller LH
    Coron Artery Dis; 2010 Nov; 21(7):391-6. PubMed ID: 20634693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).
    Pop-Busui R; Lombardero M; Lavis V; Forker A; Green J; Korytkowski M; Sobel BE; Jones TL;
    Am J Cardiol; 2009 Jul; 104(1):52-8. PubMed ID: 19576321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
    Pop-Busui R; Lu J; Lopes N; Jones TL;
    J Peripher Nerv Syst; 2009 Mar; 14(1):1-13. PubMed ID: 19335534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).
    Schwartz L; Kip KE; Alderman E; Lu J; Bates ER; Srinivas V; Bach RG; Mighton LD; Feit F; King S; Frye RL;
    Am J Cardiol; 2009 Mar; 103(5):632-8. PubMed ID: 19231325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes).
    Chung SC; Hlatky MA; Faxon D; Ramanathan K; Adler D; Mooradian A; Rihal C; Stone RA; Bromberger JT; Kelsey SF; Brooks MM;
    J Am Coll Cardiol; 2011 Aug; 58(8):810-9. PubMed ID: 21835316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.
    Hlatky MA; Melsop KA; Boothroyd DB;
    Am J Cardiol; 2006 Jun; 97(12A):59G-65G. PubMed ID: 16813739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.